Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087578 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lorenzo Flori und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Fibronectins, Lipodystrophy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this paper, we present the development of a computer-based repurposing approach to identify FDA-approved drugs that are potentially able to interfere with irisin dimerization. It has been established that altered levels of irisin dimers are a pure hallmark of lipodystrophy (LD) syndromes. Accordingly, the identification of compounds capable of slowing down or precluding the irisin dimers’ formation could represent a valuable therapeutic strategy in LD. Combining several computational techniques, we identified five FDA-approved drugs with satisfactory computational scores (iohexol, XP score = −7.70 kcal/mol, SP score = −5.5 kcal/mol, ΔGbind = −61.47 kcal/mol, ΔGbind (average) = −60.71 kcal/mol; paromomycin, XP score = −7.23 kcal/mol, SP score = −6.18 kcal/mol, ΔGbind = −50.14 kcal/mol, ΔGbind (average) = −49.13 kcal/mol; zoledronate, XP score = −6.33 kcal/mol, SP score = −5.53 kcal/mol, ΔGbind = −32.38 kcal/mol, ΔGbind (average) = −29.42 kcal/mol; setmelanotide, XP score = −6.10 kcal/mol, SP score = −7.24 kcal/mol, ΔGbind = −56.87 kcal/mol, ΔGbind (average) = −62.41 kcal/mol; and theophylline, XP score = −5.17 kcal/mol, SP score = −5.55 kcal/mol, ΔGbind = −33.25 kcal/mol, ΔGbind (average) = −35.29 kcal/mol) that are potentially able to disrupt the dimerization of irisin. For this reason, they deserve further investigation to characterize them as irisin disruptors. Remarkably, the identification of drugs targeting this process can offer novel therapeutic opportunities for the treatment of LD. Furthermore, the identified drugs could provide a starting point for a repositioning approach, synthesizing novel analogs with improved efficacy and selectivity against the irisin dimerization process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
- Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
ORCID-Profile: Lorenzo Flori, Simone Brogi, Hajar Sirous
Zitieren
APA
Flori, L., Brogi, S., Sirous, H., & Calderone, V. (2023). Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087578
Vancouver
Flori L, Brogi S, Sirous H, Calderone V. Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087578
BibTeX
@article{Flori2023,
author = {Flori, Lorenzo and Brogi, Simone and Sirous, Hajar and Calderone, Vincenzo},
title = {Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087578}
}
EUVIMED